Voyager Therapeutics (NASDAQ:VYGR) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report report published on Tuesday morning,RTT News reports. The brokerage currently has a $9.00 price target on the stock, down from their previous price target of $11.00.

A number of other research firms have also recently weighed in on VYGR. Leerink Partners started coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Citigroup began coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Monday, January 27th. Finally, Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.72.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $4.20 on Tuesday. The firm has a market capitalization of $229.45 million, a PE ratio of 5.92 and a beta of 0.91. Voyager Therapeutics has a one year low of $4.13 and a one year high of $10.66. The stock’s 50 day moving average price is $5.69 and its 200 day moving average price is $6.33.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the company posted ($0.59) earnings per share. On average, analysts forecast that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 10,778 shares of company stock worth $58,548 over the last 90 days. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VYGR. Erste Asset Management GmbH acquired a new position in shares of Voyager Therapeutics during the third quarter valued at $6,192,000. Raymond James Financial Inc. bought a new stake in Voyager Therapeutics in the 4th quarter valued at about $746,000. Barclays PLC boosted its stake in Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares during the period. Verition Fund Management LLC bought a new position in Voyager Therapeutics in the 3rd quarter worth about $216,000. Finally, Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock valued at $18,232,000 after purchasing an additional 29,014 shares during the period. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.